Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel compound and medical compositions for treating tuberculosis comprising the same

A medicinal composition and a technology for tuberculosis, which are applied in the field of compositions for the prevention or treatment of tuberculosis, and can solve problems such as the lack of replacement in effect and the like

Inactive Publication Date: 2018-11-13
SOONCHUNYANG UNIV IND ACAD COOP FOUND
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, although several second-line anti-tuberculosis agents have been developed, there is no agent that can replace the first-line agents in terms of efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compound and medical compositions for treating tuberculosis comprising the same
  • Novel compound and medical compositions for treating tuberculosis comprising the same
  • Novel compound and medical compositions for treating tuberculosis comprising the same

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0080] Preparation Example 1: Synthesis of Compound (SCH1702) of Chemical Formula 2

[0081] The compound of Chemical Formula 2 (SCH1702) was synthesized by the method shown in Reaction Formula 1 below.

[0082] Reaction 1:

[0083]

[0084] In the above reaction formula 1, 3,4-dimethoxyphenylacetic acid (Homoveratricacid) represented by chemical formula A and 4-butoxybenzaldehyde (4-butoxybenzaldehyde) represented by chemical formula B are made with triethylamine ( triethylamine, Et 3 N), acetic anhydride (Acetic anhydride, Ac 2 O) together in N 2 The reaction was carried out under the conditions of 10 hours, filtered with a filter after cooling, and then purified with EtOAc to obtain a yellow compound (Process 1-1).

[0085] Add thionyl chloride (thionyl chloride, SOCl 2 ), made to react for 40 minutes, concentrated in vacuo, removed the solvent, added pyridine (pyridine) and methanol again, and reacted again in the ice tank for 40 minutes to obtain a compound repres...

Embodiment 1

[0097] Example 1: Evaluation of anti-tuberculosis function

[0098] The anti-tuberculosis function was double confirmed by REMA (Resazurin microtiter assay: resazurin microtiter assay) and MGIT method.

[0099] 1) Preparation of Resazurin solution

[0100] Put 4mg of resazurin sodium salt (resazurin sodium salt, sigma-aldrich) into 40ml of sterilized water, after preparing 0.01% resazurin solution, filter with 0.45 μm filter, thus prepared resazurin ( Resazurin) solution, use after refrigerated storage.

[0101] 2) Preparation of tuberculosis and drug-resistant tuberculosis

[0102] H37Ra (Mycobacterium tuberculosis H37Ra: Mycobacterium tuberculosis H37Ra), H37Rv (Mycobacterium tuberculosis H37Rv: Mycobacterium tuberculosis H37Rv), extensively drug-resistant tuberculosis (XDR-TB) bacteria, isoniazid-resistant tuberculosis ( Isoniazid-resistant tuberculosis (INHr-TB) bacteria, Rifampin-resistant tuberculosis (RIFr-TB) bacteria, pyrazinamide-resistant tuberculosis (PZAr-T...

Embodiment 2

[0157] Example 2: Cytotoxicity Evaluation

[0158] Cytotoxicity was measured in THP-1, Raw264.7, L929 and HEK-293 cells associated with tuberculosis infection and proliferation. Take 10x 10 4 Cells / well (cells / well), SCH1702 (S type) were treated in DMEM medium, and cultured for 24 hours and 48 hours. As a new medium, 500 μl of medium and 5 μl of MTT solution were added to a 24-well plate, and further reacted for four hours. After the culture medium was removed, formazan was dissolved in 200 μl of DMSO, and the absorbance was measured at a wavelength of 540 nm using a microplate reader (microplate reader), expressed as 50% toxic concentration (CC 50 , 50% Cytotoxic concentration) marked cytotoxicity, and in Figure 4 The results are shown in . The measured values ​​are all the average values ​​after repeating the experiment three times, and the results are shown. refer to the Figure 4 , it can be confirmed that the compound of SCH1702 (S type) has almost no cytotoxicity...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a compound represented by a Chemical Formula 2 and the use of the compound represented by the Chemical Formula 2 for the prevention or treatment of tuberculosis. The compound represented by Chemical Formula 2 having antitubercular activity is excellent in activity against a tuberculosis strain and a drug-resistant tuberculosis strain, has low cytotoxicity, and canbe used as a pharmaceutical composition for preventing or treating tuberculosis.

Description

technical field [0001] The present invention relates to a novel compound and a composition for preventing or treating tuberculosis comprising the novel compound. Background technique [0002] At present, 1 / 3 of the world's population is infected with tuberculosis with a long history. When these people are infected with AIDS and other diseases and their immune function is weakened, they will become tuberculosis patients at any time. Currently, there are an estimated 16 million patients worldwide, and 8 million new tuberculosis patients are diagnosed each year. In addition, among these people, 2 million people die every year. [0003] In developed countries, the tuberculosis infection rate is less than 0.1%, and the incidence rate is also less than 25%. The prevalence of active tuberculosis in Korea (prevalence based on X-ray imaging) decreased from 5.1% in 1965 to 1.0% in 1995, the prevalence of positive tuberculosis decreased from 0.94% to 0.22%, and the annual risk of tub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D207/28A61K31/4015A61P31/06
CPCA23L33/127C07D207/28A23V2002/00A23V2200/314A23V2250/30A23L33/10A61K31/4015A23V2200/30
Inventor 宋镐年南穷祐李炳义徐勋熙
Owner SOONCHUNYANG UNIV IND ACAD COOP FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com